Grail has appointed George Golumbeski to serve as president of the Menlo Park, CA, cancer test developer. He has also joined Grail’s board of directors. Golumbeski was most recently executive vice president of business development at Celgene (NYSE: [[ticker:CELG]]). In May, Grail closed a $300 million Series C round of financing to continue its work to develop and validate a blood test that can detect cancer early.
Author: Frank Vinluan
Xconomy Editor Frank Vinluan is a business journalist with experience covering technology and life sciences. Based in Raleigh, he was a staff writer at the Triangle Business Journal covering technology, biotechnology and energy before joining MedCityNews.com as North Carolina bureau chief. Prior to moving to North Carolina’s Research Triangle in 2007 he held business reporting positions at The Des Moines Register and The Seattle Times.
View all posts by Frank Vinluan
